TABLE 2.
CALCITONIN | PLACEBO | ||||
---|---|---|---|---|---|
N | Mean (SD) | N | Mean (SD) | p | |
TOTAL BODY | |||||
Screening to 18 mos | |||||
ZTBBMDscreening | 30 | −1.27 (0.92) | 32 | −1.24 (0.75) | 0.89 |
ZTBBMD18 | 23 | −1.45 (0.9) | 26 | −1.29 (0.82) | 0.53 |
ΔZTBBMD(18-0) | 22 | −0.21 (0.59) | 26 | 0.00 (0.51) | 0.3 |
Screening to 9 mos | |||||
ZTBBMD9 | 23 | −1.4 (0.87) | 23 | −1.24 (0.92) | 0.56 |
ΔZTBBMD(9-0) | 22 | −0.1 (0.51) | 23 | 0.02 (0.5) | 0.63 |
Screening to 18 mos (bone age adjusted) | |||||
ZTBBMD (BA)screening | 28 | −0.95 (1.01) | 27 | −0.93 (0.78) | 0.96 |
ZTBBMD (BA)18 | 21 | −0.9 (0.94) | 20 | −1.05 (0.84) | 0.58 |
ΔZTBBMD(BA)(18-0) | 21 | −0.13 (0.69) | 21 | −0.21 (0.62) | 0.71 |
SPINE | |||||
Screening to 18 mos | |||||
ZSBMDscreening | 31 | −1.55 (0.69) | 32 | −1.53 (0.75) | 0.95 |
ZSBMD18 | 26 | −1.34 (0.66) | 29 | −1.33 (0.87) | 0.89 |
ΔZSBMD(18-0) | 26 | 0.19 (0.53) | 29 | 0.18 (0.5) | 0.95 |
Screening to 9 mos | |||||
ZSBMD9 | 23 | −1.44 (0.56) | 23 | −1.52 (0.8) | 0.69 |
ΔZSBMD(9-0) | 23 | 0.17 (0.38) | 23 | 0.00 (0.49) | 0.18 |
Screening to 18 mos (bone age adjusted) | |||||
ZSBMD (BA)screening | 29 | −1.28 (0.68) | 27 | −1.16 (0.87) | 0.57 |
ZSBMD(BA)18 | 21 | −0.92 (0.64) | 19 | −1.17 (0.87) | 0.3 |
ΔZSBMD(BA)(18-0) | 21 | 0.31 (0.62) | 21 | 0.03 (0.72) | 0.18 |
SD: standard deviation, ZTBBMD: Total body BMD Z-score, ΔZTBBMD: change in total body BMD Z-score from screening to 9 or 18 mos, ZSBMD: Spine BMD Z-score, ΔZTBBMD: change in spine BMD Z-score from screening to 9 or 18 mos, (BA): adjusted for bone age Italicized: primary outcomes